TY -的T1 -包含bedaquiline方案和delamanid相比,耐药结核病患者bedaquiline JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01181 -2019欧元六世- 55 - 1 SP - 1901181 AU Olayanju Olatunde盟——提出Aliasgar AU - Limberis,杰森盟——Dheda克尔坦Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/55/1/1901181.abstract N2 -关于德拉曼尼和贝达奎林联合用于耐药结核病(DR-TB)方案的数据有限。没有前瞻性的长期结果数据，包括艾滋病毒感染者的数据。2014年至2018年，我们前瞻性地随访了122名有耐药结核和预后不良特征的南非患者(52.5%为hiv感染者)。我们对接受以贝达奎林为基础的治疗方案(n=82)与接受贝达奎林-德拉曼尼联合治疗方案(n=40)的疗效和安全性进行了比较。6个月培养转化率无显著差异(92.5% vs 81.8%;p=0.26)和18个月的有利转归率(63.4%对67.5%;p=0.66)，但后者的耐药程度更高(对至少5种药物的耐药程度分别为3.7%和22.5%;p=0.001)和更高的治疗前失败率(12.2% vs 52.5%治疗前耐多药结核病治疗失败;术中,0.001)。虽然联合组用Fridericia公式修正的QT间期延长比例较高(与基线相比为60 ms (p=0.001)或治疗期间为450 ms (p=0.001))，但两组均无症状病例或停药。 Results were similar in HIV-infected patients.A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline–delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo ER -